sEphB4-HSA in Treating Patients With Kaposi Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
Skin Kaposi Sarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BEHAVIORAL

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Recombinant EphB4-HSA Fusion Protein

Given IV

Trial Locations (9)

21205

Johns Hopkins University, Baltimore

30303

Grady Health System, Atlanta

33136

University of Miami, Miami

60612

John H. Stroger Jr., Hospital of Cook County, Chicago

63110

Washington University, St Louis

90025

UCLA CARE Center, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

UCSD Moores Cancer Center, La Jolla

98101

Virginia Mason Medical Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Vasgene Therapeutics, Inc

INDUSTRY

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of Arkansas

OTHER

lead

AIDS Malignancy Consortium

NETWORK

NCT02799485 - sEphB4-HSA in Treating Patients With Kaposi Sarcoma | Biotech Hunter | Biotech Hunter